“The sponsor has conducted single-dose toxicity studies in rats and repeat-dose toxicity studies in rats and minipigs.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Why that species
Comparable metabolism data support rat and minipig as suitable models
“These data support the use of the minipig and rat as suitable nonclinical animal models in which to assess the potential toxicity of abametapir.”
✓ VerifiedFDA pharmacology/toxicology review, p. 30Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“Once daily dermal administration of abametapir lotion, 0.74% in female minipigs for 28 days was without systemic effects”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Species: general tox
Rat (oral) and minipig (dermal)
“Also the duration of treatment is much greater in the oral rat and dermal minipig studies (i.e., 14 to 28 days) compared to clinical conditions of use (single 10 minute application that is washed off).”
✓ VerifiedFDA pharmacology/toxicology review, p. 56Source ↗
Species: DART
Rat and rabbit (oral)
“Abametapir has been tested for reproductive and developmental toxicology in rats and rabbits after oral administration with no significant findings independent of maternal toxicity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Species: carcinogenicity
Not conducted (single-use, non-chronic product)
“No carcinogenicity studies were included in this NDA submission. Abametapir lotion is intended as a single use drug product.”
✓ VerifiedFDA pharmacology/toxicology review, p. 50Source ↗
Surrogate used in
No surrogate used
“Once daily dermal administration of abametapir lotion, 0.74% in female minipigs for 28 days was without systemic effects”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗